Read More

Ionis and Astrazeneca’s Eplontersen Demonstrated a Statistically Significant and Clinically Meaningful Change From Baseline for Co-primary and Secondary Endpoints at 35 Weeks vs External Placebo Group

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today presented positive results from a planned 35-week interim analysis of the Phase 3 NEURO-TTRansform study of Ionis and AstraZeneca's eplontersen in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).